Thane Wettig
Chief Executive Officer bei FIBROGEN, INC.
Vermögen: 1 Mio $ am 31.03.2024
Profil
Thane Wettig is currently the Chief Executive Officer & Director at FibroGen, Inc. He previously worked as the Chief Commercial Officer at Intarcia Therapeutics, Inc. and as the Vice President-Diabetes Brands Global Marketing at Lilly Diabetes from 2004 to 2009.
Mr. Wettig completed his undergraduate degree and MBA at Washington University in St. Louis.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
FIBROGEN, INC.
0,48% | 22.03.2024 | 470 396 ( 0,48% ) | 1 Mio $ | 31.03.2024 |
Aktive Positionen von Thane Wettig
| Unternehmen | Position | Beginn |
|---|---|---|
| FIBROGEN, INC. | Chief Executive Officer | 23.07.2023 |
Ehemalige bekannte Positionen von Thane Wettig
| Unternehmen | Position | Ende |
|---|---|---|
| Lilly Diabetes | Corporate Officer/Principal | 01.01.2009 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Ausbildung von Thane Wettig
| Washington University in St. Louis | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
| Lilly Diabetes |
